Amesbury, UK – Nanoparticle characterization company NanoSight has been acquired by Malvern Instruments. The acquisition was completed on Friday, September 27.
NanoSight developed and commercialized a special technology called Nanoparticle Tracking Analysis (NTA). The company’s instrumentation and software enable the rapid and simultaneous multi-parameter analysis and characterization of many different types of nanoscale particles. With their ability to analyze particle size, concentration, zeta potential and aggregation, NanoSight systems are closely aligned with Malvern’s market-leading Zetasizer range, extending Malvern’s solutions for those working at the nanoscale.
Currently the largest applications area for NTA is in life sciences, for the measurement of biological nanoparticles, where one of the most rapidly expanding fields is exosomes. These are intercellular messengers whose quantity and biochemical composition reflect the disease status of an individual. NanoSight technology provides quantitative detection and characterization capabilities to make exosomes a viable proposition as biomarkers for drug discovery, disease prognosis, diagnosis and monitoring as well as personalized medicine.
“The plans we have are ambitious and exciting, and the support and reach of the Malvern organization will allow us to grow more rapidly than we could alone,” said Jeremy Warren, CEO of NanoSight.
NanoSight employs around 50 people worldwide and says it will continue to operate from its current facilities in the UK, under the existing management team.